WALTHAM, Mass., Sept. 20, 2021 /PRNewswire/ -- Thermo Fisher
Scientific (NYSE: TMO), the world leader in serving science, today
launched the Applied Biosystems QuantStudio Absolute Q Digital PCR
System, the first fully integrated digital PCR (dPCR) system
designed to provide highly accurate and consistent results within
90 minutes.
The QuantStudio Absolute Q provides an industry-best dPCR
platform accelerating innovation in cancer research and more.
dPCR has quickly become the standard for nucleic acid
quantification in oncology, cell and gene therapy development and
other research applications because its absolute quantification
enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and
its cutting-edge dPCR technology to rapidly develop and
commercialize it alongside an expanding portfolio of assays.
The dPCR technology that powers the QuantStudio Absolute Q
solution is already in use by biotech companies and academic
institutions for longitudinal monitoring of cancer-driving
mutations in liquid biopsy, precise quantification of gene inserts
for cell therapy development, and copy number variation studies for
earlier identification of genetic conditions in newborns.
"These early adopters of dPCR technologies have faced
limitations, including error-prone operation, imprecision and poor
turnaround times," said Mark
Stevenson, executive vice president and chief operating
officer of Thermo Fisher Scientific. "For our customers, the
QuantStudio Absolute Q Digital PCR System overcomes these
limitations and provides an industry-best dPCR platform to enable
accelerated innovation in cancer research, rare diseases and much
more."
Philip Lee, Chief Technology
Officer, Senti Biosciences said
"Accurate measurement of genetic biomarkers is critical to Senti
Biosciences' gene circuit technology. We adopted this novel
solution for its fast and simple workflow, which makes a
significant difference in generating consistent and accurate data
quickly. It was straightforward to implement, and new users
can generate the data that we need with ease."
Unlike complex, multi-instrument workflows required for
traditional dPCR, the QuantStudio Absolute Q System uses
microfluidic array technology and simplified workflows, designed to
improve data accuracy and consistency. Hands-on time is just five
minutes, minimizing the risk of user error.
For more information, please visit
www.thermofisher.com/digitalpcr.
* For research use only. Not for use in diagnostic
procedures
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue of approximately $35 billion. Our Mission is to enable our
customers to make the world healthier, cleaner and safer. Whether
our customers are accelerating life sciences research, solving
complex analytical challenges, improving patient diagnostics and
therapies or increasing productivity in their laboratories, we are
here to support them. Our global team of more than 90,000
colleagues delivers an unrivaled combination of innovative
technologies, purchasing convenience and pharmaceutical services
through our industry-leading brands, including Thermo Scientific,
Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab
Services and Patheon. For more information, please
visit www.thermofisher.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-adds-digital-pcr-to-genetic-analysis-capabilities-301380061.html
SOURCE Thermo Fisher Scientific